Galmed Pharmaceuticals Ltd.

GLMD

IL0011313900

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-17 pm EDT			5-day change	1st Jan Change
1.675 ^USD	-2.90%		+3.40%	-47.49%

May. 27	Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash	CI
May. 22	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Top Midday Gainers

Published on 04/28/2025 at 13:54, updated on 04/28/2025 at 13:55

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Galmed Pharmaceuticals Ltd.

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash	May. 27	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 22	CI
Galmed Pharmaceuticals Ltd. Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models	May. 13	CI
Galmed Announces First Time Results In Oncology Studies Aramchol Significantly Enhances Bayer's Regorafenib Effect In Gi Cancer Models	May. 06	RE
Galmed Pharmaceuticals Ltd. Announces First Time Results in Oncology Studies	May. 06	CI
Top Midday Gainers	Apr. 28	MT
Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up	Apr. 28	MT
Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation	Apr. 28	RE
Galmed Pharmaceuticals Ltd. Signs Term Sheet for the Development of Novel Semaglutide Sublingual Formulation	Apr. 28	CI
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers	Apr. 17	RE
Galmed Pharmaceuticals Launches Vcu Collaboration to Tackle Drug Resistance in GI Cancers	Apr. 17	CI
Galmed Pharmaceuticals Ltd. Unveils Novel Pharmacodynamic Blood Markers for Aramchol	Apr. 15	CI
Galmed Pharmaceuticals Ltd. Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor	Apr. 10	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 02	CI
Galmed Pharmaceuticals Ltd. Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in Nash/Mash Combination Therapy	Mar. 20	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 14	CI
Galmed Pharmaceuticals Ltd. Publishes Results from Aramchol Phase 3 Open Label Part in Hepatology	24-09-25	CI
Wall Street Recovers From Rate Cut-Fueled Losses, Driving Premarket Gains for US Equity Futures	24-09-19	MT
Top Premarket Gainers	24-09-19	MT
Top Premarket Decliners	24-09-18	MT
Top Premarket Gainers	24-09-17	MT
Galmed Pharmaceuticals Ltd. announced that it expects to receive $9.999793 million in funding from Yorkville Advisors Global LP	24-08-29	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-28	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-30	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-04	CI

Chart Galmed Pharmaceuticals Ltd.

Duration

Period

GLMD: Dynamic Chart

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Employees

Sector

Biotechnology & Medical Research

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company